Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Newsoara BioPharma Expands Global Rights to vTv’s PDE4 Inhibitor HPP737 in $135 Million Deal

Fineline Cube Feb 11, 2026
Company Deals Medical Device

Siemens Healthineers Partners with Northwestern Medicine to Advance Precision Cancer Care

Fineline Cube Feb 11, 2026
Company Deals

Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III

Fineline Cube Feb 11, 2026
Company Deals

uBriGene Biosciences Partners with Innovec Biotherapeutics on AAV Gene Therapy for Hereditary Eye Diseases

Fineline Cube Feb 11, 2026
Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Fineline Cube Feb 11, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

SciClone’s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer

Fineline Cube Feb 11, 2026
Company Drug

Hengrui Pharma’s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication

Fineline Cube Feb 11, 2026
Policy / Regulatory

CDE Launches Technical Guidelines to Emphasize Patient-Centered Drug Clinical Trials

Fineline Cube Jul 28, 2023

The Center for Drug Evaluation (CDE) has released a series of Technical Guidelines that encompass...

Company Drug

Eli Lilly’s Donanemab Shows Significant Slowdown in Alzheimer’s Disease Progression in Phase III Study

Fineline Cube Jul 28, 2023

US pharmaceutical major Eli Lilly and Company (NYSE: LLY) has revealed the complete results of...

Company Drug

Jiangsu Simcere Pharmaceutical Receives NMPA Approval for Atopic Dermatitis Drug SIM0278

Fineline Cube Jul 28, 2023

China’s Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced that it has received clinical...

Company Deals Policy / Regulatory

Pingshan District and Fosun Pharma Ink Strategic Deal to Boost Biomedical Industry

Fineline Cube Jul 28, 2023

The People’s Government of Pingshan District in Shenzhen has signed a cooperation framework agreement with...

Company Drug

CanSino Biotechnology Receives NMPA Approval for Tetanus Vaccine CS-2047

Fineline Cube Jul 28, 2023

China-based vaccines specialist CanSino Biotechnology Inc., (HKG: 6185) has announced that it has received clinical...

Company Deals

SanReno Therapeutics Partners with WuXi STA for Comprehensive R&D and Manufacturing Services

Fineline Cube Jul 28, 2023

Shanghai-based kidney drug developer SanReno Therapeutics has entered into a partnership with WuXi STA, a...

Company Deals

Chongqing Zhifei Biological Partners with PT Bio Farma for Global Tuberculosis Vaccine Development

Fineline Cube Jul 28, 2023

China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has entered into a global cooperation memorandum...

Company Drug

BRL Medicine Inc. Receives IND Approval for CD19-Targeted CAR-T Therapy BRL-301 from CDE

Fineline Cube Jul 28, 2023

Shanghai-based BRL Medicine Inc. has announced that it has received Investigational New Drug (IND) approval...

Company

Bristol-Myers Squibb Q2 2023 Results Miss Estimates, Full-Year Guidance Revised Downward

Fineline Cube Jul 28, 2023

US pharmaceutical company Bristol-Myers Squibb (BMS; NYSE: BMY) has released its financial report for the...

Company

Pfizer Announces Leadership Shake-Up with Focus on Oncology R&D

Fineline Cube Jul 28, 2023

Pfizer Inc., (NYSE: PFE) has announced significant changes in its Research and Development (R&D) leadership....

Company

Roche Group’s H1 2023 Financial Report: Pharmaceuticals Grow While Diagnostics Dip

Fineline Cube Jul 28, 2023

Swiss pharmaceutical giant Roche Group (SWX: ROG) has released its half-yearly financial report for 2023,...

Company Drug

MSD’s V116 Vaccine Shows Superior Immune Response in Phase III Trials

Fineline Cube Jul 28, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK) has revealed positive topline results from two Phase...

Company Deals

Pharmaniaga Berhad and CSPC Pharmaceutical Group Broaden Collaboration in Pharma and Biopharma

Fineline Cube Jul 27, 2023

Malaysia-based pharmaceutical company Pharmaniaga Berhad has announced the signing of a comprehensive collaboration with China’s...

Company

Thermo Fisher Scientific Reports Q2 2023 Revenue Dip, Adjusts Full-Year Forecast

Fineline Cube Jul 27, 2023

US-based life sciences giant Thermo Fisher Scientific Inc. (NYSE: TMO) has released its financial results...

Company Deals

AbbVie and Calibr Announce Strategic Collaboration to Advance Preclinical Research

Fineline Cube Jul 27, 2023

AbbVie (NYSE: ABBV) and US-based Calibr, the nonprofit drug discovery division of San Diego research...

Company

GSK Reports 4% YOY Sales Growth in Q2 2023, Upgrades Full-Year Guidance

Fineline Cube Jul 27, 2023

UK-based pharmaceutical giant GlaxoSmithKline plc (GSK, NYSE: GSK) has released its financial report for the...

Company Drug

Everest Medicines Launches Xerava Antibiotic in China, Marking Commercial Milestone

Fineline Cube Jul 27, 2023

Everest Medicines (HKG: 1952) has announced the commercial launch of its Xerava (eravacycline) antibiotic in...

Company Drug

Jiangsu Recbio’s Shingles Vaccine REC610 Accepted for Review by China’s NMPA

Fineline Cube Jul 27, 2023

Jiangsu Recbio Technology Co., Ltd, a China-based company, has announced that the National Medical Products...

Company Deals

Mirxes Holding Company Secures USD 50 Million in Series D Financing for RNA Technology

Fineline Cube Jul 27, 2023

Mirxes Holding Company Ltd, a Singapore-headquartered RNA technology company specializing in blood-based miRNA test kit...

Company Drug

Shanghai Henlius Completes Phase I/II Study for Anti-VEGF mAb HLX04-O in Wet AMD

Fineline Cube Jul 27, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary, Shanghai Henlius Biotech, Inc....

Posts pagination

1 … 454 455 456 … 623

Recent updates

  • Newsoara BioPharma Expands Global Rights to vTv’s PDE4 Inhibitor HPP737 in $135 Million Deal
  • Siemens Healthineers Partners with Northwestern Medicine to Advance Precision Cancer Care
  • SciClone’s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer
  • Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III
  • Hengrui Pharma’s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Newsoara BioPharma Expands Global Rights to vTv’s PDE4 Inhibitor HPP737 in $135 Million Deal

Company Deals Medical Device

Siemens Healthineers Partners with Northwestern Medicine to Advance Precision Cancer Care

Company Drug

SciClone’s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer

Company Deals

Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.